Rodent models of laser-induced choroidal neovascularization (CNV) are now extensively used to identify angiogenic proteins, determine the role of speci®c genes with knockout mice, and evaluate the ef®cacy and safety of anti-angiogenic therapies. CNV is typically evaluated by¯uorescein angiography or vascular endothelial cell labeling in histologic sections. The current study examined an alternative method using high molecular weight FITC-dextran (MW 2 Â 10 6 ) for high resolution angiography in RPE-choroid-sclera¯at mounts. At 24 hr after lasering, the lesions appeared as a circular weaklȳ uorescent area of approximately equal diameter to the laser spot. No FITC-dextran labeled blood vessels were visible in the lesion at day 1. Three days after lasering, 47 % of the lesions showed FITC-dextran labeling indicative of CNV. The incidence (71 %) and extent of CNV increased by day 6, and by day 10 all lesions were vascularized, and the maximal area was attained. No signi®cant change followed day 10, and the neovascular area remained constant through day 31. The highest rate of blood vessel growth (between 3 and 10 days after laser) correlates with the peak expression of VEGF, bFGF, and their receptors shown in previous studies. Morphologic analysis of¯at mounts and histologic sections showed that the neovascular plexus in most lesions originates from deeper choroidal vessels in the center of the lesion, grows towards the neural retina, then branches circumferentially to anastamose with uninjured choriocapillaris. The microvessels in these lesions are broad and¯at, similar to normal choriocapillaris. In a separate study, rats were treated daily with the angiostatic corticosteroid dexamethasone (20±500 mg kg À1 day
Introduction
The protein extravasation and hemorrhage associated with choroidal neovascularization (CNV) are primary causes of severe vision loss in retinal diseases such as age-related macular degeneration (ARMD) (D'Amico, 1994; Lee, Wang and Adamis, 1998) . In ARMD, the normal barrier function of Bruch's membrane is compromised, and CNV can develop either under the retinal pigment epithelium (RPE) or within the subretinal space between RPE and photoreceptor outer segments. Recent experimental and clinical efforts have focused on developing therapeutic strategies for exudative ARMD that either obstruct perfusion or inhibit the growth of new choroidal blood vessels (Miller et al., 1995; Seo et al., 1999) . As novel anti-angiogenic therapies become available, animal models of CNV are required to evaluate their local and systemic toxicity and ef®cacy.
An established model of CNV is laser photocoagulation of the RPE and choroid in primates (Ryan, 1979) and rodents (Dobi, Pulia®to and Destro, 1989; Frank, Das and Weber, 1989; Seo et al., 1999) . Laser photocoagulation selectively ablates the photoreceptor outer segments, RPE, choriocapillaris, and portions of the anterior choroid. The subsequent wound response includes the ingrowth of ®broblasts, RPE, and vascular endothelial cells that form a de®ned neovascular lesion. Previous studies have characterized these in®ltrating cell types and have identi®ed the expression of vascular endothelial growth factor, ®broblast growth factor, and other proteins typically associated with new blood vessel growth (Nishimura et al., 1990; Zhang, Samadani and Frank, 1993; Ishibashi et al., 1995 Ishibashi et al., , 1997 Ogata et al., 1996 Ogata et al., , 1997 Yi et al., 1996) . Tobe et al. (1998) showed that basic ®broblast growth factor was not required for laser-induced CNV in knockout mice lacking this angiogenic protein.
Laser-induced CNV has also been used to evaluate inhibitors of angiogenesis in rodents (Seo et al., 1999; Takehana et al., 1999) and to evaluate photodynamic therapy in primates (Miller et al., 1995) . The predominant methods of determining ef®cacy in these studies and in knockout mice are¯uorescein angiography and histology using serial cross sections. Both of these methods have technical limitations. Conventional¯uorescein angiography is not amenable to high resolution analysis and is not easily quanti®ed. Furthermore, the relationship between blood vessel growth, vascular permeability, and uorescein leakage in these models has not been carefully studied. Histologic analysis of CNV is commonly used, but adequate sampling of histologic sections and quantifying blood vessel growth is technically dif®cult and extremely labor intensive (Seo et al., 1999) . A method that readily measures experimental CNV with high resolution would accelerate the discovery of genes and anti-angiogenic therapies that modulate choroidal neovascularization.
Fluorescein isothiocyanate (FITC)-dextrans of high molecular weight (MW 2 Â 10 6 ) are retained within blood vessels after ®xation and can be used to label vascular volume (D'Amato, Wesolowski and Smith, 1993; Smith et al., 1994) . This method of high resolution angiography was used to measure blood vessel growth in retinal¯at mounts from a mouse model of oxygen-induced retinopathy (Smith et al., 1994) . Similar to retinal vessel growth in mouse, the newly formed choroidal vessels in the rat laser model of CNV grow roughly parallel to the retinal layers and RPE (Dobi et al., 1989) . Therefore, high resolution angiography may also be applied to visualizing CNV in RPE-choroid¯at mounts. The goals of the current study were to validate this method, to establish the temporal and spatial growth of CNV after lasering, and to compare the effect of an angiostatic compound on CNV in FITC-dextran¯at mounts and histologic cross sections.
Materials and Methods

Argon Laser-induced CNV in Rats
All animal studies conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and they were approved by the Animal Care Committee at Allergan. To induce choroidal neovascularization, male Brown Norway rats weighing between 200 and 300 g were anesthetized by intramuscular injection of ketamine (100 mg kg
À1
) and xylazine (10 mg kg À1 ), and both pupils were dilated with 1 % Tropicamide. Celluvisc (Allergan Inc., Irvine, CA, U.S.A.) was applied to each eye, and a glass coverslip was placed orthogonal to the visual axis. The retina was viewed through a slit lamp microscope, and the optic nerve head was centered into the microscope ®eld. Both eyes received 3 or 4 laser burns between retinal vessels around the optic nerve head using the blue-green setting of a Coherent Novus 2000 Argon Laser (Coherent, Inc., Santa Clara, CA, U.S.A.). The laser power was 90 mW for 100 ms, and the spot diameter was 100 mm. In drug studies, the test group received dexamethasone (Sigma, St. Louis, MO, U.S.A.) in approximately 1 ml corn oil once daily by oral gavage, and the control group received corn oil only.
Visualizing and Quantifying CNV using FITC-dextran Labeling
Blood vessels were labeled by vascular perfusion with high molecular weight¯uorescein isothiocyanate (FITC)-dextran (2 Â 10 6 MW; Sigma, St. Louis, MO, U.S.A.) by a method similar to that described previously (D'Amato et al., 1993) . Rats were killed with 100 % CO 2 , and approximately 50 ml of lactated Ringer was injected via the left ventricle, followed by 20 ml of 10 % gelatin with 5 mg ml À1 of FITCdextran in lactated Ringer. The eyes were cooled by aerosol refrigerant and stored in 10 % formalin. RPEchoroid-sclera¯at mounts were obtained by hemisecting the eye and peeling the neural retina away from the underlying RPE. Four radial cuts allowed the eyecup to be laid¯at onto a microscope slide with the RPE-side facing up. Flat mounts were dehydrated in ETOH followed by xylene.
Flat mounts were visualized using the 20Â objective of an epi¯uorescent compound microscope ®tted with the appropriate excitation and emission ®lters (Nikon Eclipse E600; A. G. Heinze, Irvine, CA, U.S.A.). Images of the neovascular lesions were captured using an analog video camera (MTI 3CCD; A. G. Heinze, Irvine, CA, U.S.A.) coupled to a PC with image capture and analysis software (Image Pro 3.0, Media Cybernetics, Silver Spring, MD, U.S.A.). A calibration image was also obtained from a slide with a grating of known size. Blood vessels within the neovascular lesion that were labeled with FITCdextran (i.e. hyper¯uorescent) were highlighted, and this reproduction of the CNV was converted into a binary (black and white) image. The area (in mm 2 ) occupied by white pixels was measured and it is presented as`neovascular area'. The measurements of neovascular area obtained from multiple lesions from both eyes for each animal were averaged.
Histologic Analysis of Paraf®n-embedded Cross Sections
Paraf®n-embedded cross sections through lesions were examined using Hematoxylin/eosin (H & E) staining and Factor VIII immunostaining of vascular endothelial cells. Eyes were ®xed by perfusing 50 ml lactated Ringer and 20 ml of 4 % paraformaldehyde in phosphate-buffered saline via the left ventricle, followed by enucleation and storage of eyes overnight in 4 % paraformaldehyde. The posterior eye cup (retina-RPE-choroid-sclera) was embedded in paraf®n, and serial sections 10 mm thick were cut and used for either H & E or immunostaining. Immunostaining for Factor VIII used the rabbit polyclonal IgG antibody speci®c for human Factor VIII (Dako Corp., Carpinteria, CA, U.S.A.). After incubation with primary antibody, sections were stained using a method of horseradish peroxidase streptavidin biotin immunohistochemistry. Normal non-immune rabbit IgG was used as control for staining speci®city. Bound immunocomplexes were visualized with aminoethylcarbazole substrate chromagen (Dako). Sections were counterstained with Mayer's hematoxylin.
Statistical Analysis
All data are presented as mean+ S.D. with a minimum of three independent measurements unless otherwise noted. Statistical signi®cance was determined using a one-tailed unpaired t-test or Bonferroni multiple comparison analysis. P values 40 . 05 are considered statistically signi®cant.
Results
Angiographic Analysis of RPE-choroid-sclera Flat Mounts
Laser photocoagulation of the RPE-choroid results in experimental choroidal neovascularization (CNV) which has been characterized by in vivo angiography, histology and vascular casting (Ryan, 1979; Ohkuma and Ryan, 1983; Dobi et al., 1989; Frank et al., 1989; Miller et al., 1990 ). In the current study, FITC-dextran was used to label blood vessel lumen, and RPEchoroid-sclera¯at mounts were examined by¯uor-escence microscopy to temporally follow experimental CNV after argon laser photocoagulation.
Figs 1 and 2 show low and high magni®cation images of FITC-dextran-labeled¯at mounts. The low magni®cation image ( Fig. 1) shows that CNV in lesions around the optic nerve head appears hyperuorescent compared to the surrounding choroid which is masked by highly melinated RPE cells and choroidal melanocytes. Fig. 2 shows images obtained with higher magni®cation¯uorescence microscopy of lesions between 24 hr and 31 days after lasering. At 24 hr [ Fig. 2(A) ], the lesion shows a circular area of weak hyper¯uorescence with a diameter approximately equal to that of the laser spot (100 mm). This¯uorescence in probably due to a combination of auto¯uorescence from blood breakdown products, and¯uorescence emanating from the underlying sclera where the RPE and choroid have been thermally ablated. No FITC-dextran labeled blood vessels are visible in the lesion at day 1 (n 7, 29 lesions). ) via cardiac perfusion in rats 10 days after argon laser photocoagulation. Shown is a representativē uorescent image of four laser lesions (arrows) around the optic nerve head (ONH). The bar is 500 mm in length.
At day 3, 16/30 lesions (53 %; n 7) are hypouorescent with no visible new vessel growth; however, 14/30 lesions (47 %) contain FITC-labeled blood vessels primarily in the lesion's center [ Fig. 2(B) ]. By day 6, the proportion of lesions showing new vessel growth increases to 71 % (20/28; n 7), and the extent of neovascularization also increases [ Fig. 2(C) ]. At this time, CNV is only observed in the center of the lesion and is usually associated with pigment-laden cells, presumably macrophages. This suggests that CNV originates from deep choroidal vessels that are masked by choroidal melanocytes. The extent and incidence of neovascular labeling both increase dramatically between days 6 and 10. All lesions at day 10 are vascularized (32/32; n 7), and most show a network of broad,¯at microvessels, reminiscent of choriocapillaris, that span a circular area approximately 300 mm in diameter [ Fig. 2(D) ]. The neovascular network at day 17 (33/33 lesions; n 7) and day 31 (22/22 lesions; n 4) appears similar to that of day 10.
All lesions from days 3 to 31 were examined by computer-assisted digital image analysis to measure the area of FITC-dextran-labeled choroidal neovascularization. These data are shown graphically in Fig. 3 . Neovascular area increases from 3 . 5 + 1 . 8 Â 10 3 to 12 . 0 + 7 . 7 Â 10 3 mm 2 between days 3 and 6. Between days 6 and 10, neovascular area more than doubles to 28 . 4 + 8 . ) for each time point from lesions 3±31 days after argon laser photocoagulation. The number of rats examined in each group is denoted as n. For each rat, 3±7 lesions were averaged. There is no signi®cant difference between days 3 and 6 (P 4 0 . 05). Neovascular area at days 3 and 6 is signi®cantly different from that at days 10, 17 and 31 (P 5 0 . 05; Bonferroni multiple comparison analysis). change follows day 10, and the neovascular area is 32 . 6 + 7 . 0 Â 10 3 mm 2 at day 17, and 33 . 4 + 6 . 1 Â 10 3 mm 2 at day 31. Ten days after lasering, the majority of lesions contain a dense microvascular network that grows anterior to the RPE, resembles the broad¯at vessels of normal choriocapillaris, and anastamoses with uninjured choriocapillaris via small caliber vessels which are approximately 10 mm in diameter [ Fig. 4(A) , (B) and (D)]. In contrast, some neovascular nets are formed by sparse, smaller caliber microvessels derived from larger caliber deep choroidal vessels (40±50 mm) [ Fig. 4(C) ]. The smallest measurable microvessels in these lesions are 44 . 5 mm in diameter.
H & E and Factor VIII Immunostaining of Histologic Sections
Studies were conducted to examine more carefully the relationship between the temporal formation of FITC-dextran labeled blood vessels in¯at mounts and vascular endothelial cell and blood vessel development in histologic sections. Fig. 5 shows representative H & E-stained sections from normal retina-RPEchoroid and from lesions 2 hr to 17 days after lasering. At 24 hr after lasering, photoreceptor outer segments, RPE, and choroid have been thermally ablated, and the extent of this damage has approximately the same diameter as the laser spot (100 mm). The laser energy is absorbed primarily by photoreceptor pigment and by melanin in the RPE apical processes and choroid. No new blood vessels are present at this time. At day 3, a fusiform-shaped lesion has developed that consists primarily of pigmentladen cells, ®broblasts, vascular endothelial cells, and RPE (Zhang et al., 1993) . None of the sections examined showed blood vessel formation at day 3. In contrast, blood vessels with red blood cells are seen in the lesion by day 6. At days 10 and 17, the lesion Representative images of normal retina-RPE-choroid and images from lesions between days 1 and 17 after argon laser photocoagulation are shown. The white arrows in images from days 3, 6, 10 and 17 denote blood vessels, some of which contain red blood cells within their lumen. The black arrows denote RPE cells that grow over the inner portion of the lesion at days 10 and 17. Shown in normal retina is the photoreceptor nuclear layer (PNL), photoreceptor inner (IS) and outer (OS) segments, and retinal pigment epithelium (RPE). The bar located in the lower left corner of the day 1 image is 50 mm in length. Each image is representative of sections obtained from a minimum of two lesions from two rats.
height and width has increased, and an RPE monolayer has formed and separated the neural retina from the underlying lesion. All sections examined at these later time points showed more extensive blood vessel formation.
Factor VIII immunostaining was used to speci®cally follow the progression of vascular endothelial cell invasion into the lesion and subsequent blood vessel formation. Fig. 6 shows immunostained paraf®n-embedded cross sections of lesions between 1 and 17 days after lasering. In normal retina, Factor VIII staining is restricted to endothelial cells of large blood vessels (not shown) and microvessels of the neural retina and choriocapillaris. At 24 hr after lasering, FIG. 6 . Time course of Factor VIII immunostaining after argon laser photocoagulation. Representative images of paraf®n-embedded cross sections through normal tissue and those obtained 1, 3, 6, 10 and 17 days after lasering are shown. Factor VIII is labeled with an AEC substrate chromagen which gives a red product. Untreated (normal) eyes show strong Factor VIII staining in the neural retina (black arrow) and choriocapillaris (white arrow). The black bar located in the lower right corner of the day 17 image is 100 mm in length. Each image is representative of sections obtained from a minimum of two lesions from two rats. INL, inner nuclear layer; PNL, photoreceptor nuclear layer; RPE, retinal pigment epithelium; chor, choroid.
strong Factor VIII staining is seen at the primary site of laser injury and in the surrounding neural retina, choroid, and scleral vessels. Factor VIII is secreted around wounds as a component of the blood clotting cascade. By day 3, strong staining is observed in the choriocapillaris at the periphery of the lesion. Weaker but discrete immunostaining is observed within the lesion, and this suggests the presence of invading vascular endothelial cells. By day 6, Factor VIIIstained endothelial cells form vessels originating from deeper choroidal vasculature. Consistent with the conclusion stated above from¯uorescence labeling, this image shows a blood vessel derived from deeper choroid that spans the lesion's center radially and branches outward toward the uninjured choriocapillaris [compared with Fig. 2(C) ]. At days 10 and 17, there is an increase in the number and size of Factor VIII-stained vessels within the lesion.
These histologic data show that vascular endothelial cells invade the lesion by day 3 and form functional blood vessels by day 6. The spatiotemporal development of CNV seen in histologic sections is consistent with that seen in FITC-dextran labeled¯at mounts (Figs 2 and 3) .
Inhibition of Experimental CNV by Dexamethasone
To test the utility of FITC-dextran labeling of CNV for quantifying pharmacologic intervention, we examined the effect of dexamethasone, a proven angiostatic corticosteroid, on CNV as measured by FITC-dextran labeling and Factor VIII immunostaining. Figs 2 and 3 show that the extent of CNV reaches its maximum by day 10, and therefore, this time-point was selected as optimal for measuring drug effect. Fig. 7 shows the effect of dexamethasone (20±500 mg kg À1 day À1 by oral gavage) on experimental CNV measured in¯at mounts 10 days after lasering. Dexamethasone inhibited CNV by 48 % at 20 mg kg À1 day À1 , by 64 % at 100 mg kg À1 day À1 , and by 95 % at 500 mg kg À1 day À1 . A representative lesion from the high dose dexamethasone group (500 mg kg À1 day
À1
) is shown in Fig. 8(B) . The lesion is hypo¯uorescent and devoid of new blood vessels. Factor VIII immunostaining in histologic sections [ Fig. 8(D) ] supports this observation and shows that this dose of dexamethasone inhibited the development of an organized lesion and the invasion of vascular endothelial cells.
Discussion
Choroidal neovascularization (CNV) is associated with a change in the normal function of Bruch's membrane and retinal pigment epithelium (RPE) and causes severe vision loss in patients with age-related macular degeneration (ARMD). As ®rst reported by Ryan (1979) , laser-induced disruption of the RPE and Bruch's membrane in primates results in subretinal neovascular lesions that leak¯uorescein in angiography and show remarkable similarity to lesions in ARMD patients. This method of inducing CNV by laser was subsequently developed in rodents, and blood vessel growth was characterized by angiography, histology, and vascular casting in these models (Dobi et al., 1989; Frank et al., 1989; Seo et al., 1999) . Rodent models of laser-induced CNV are now extensively used to identify angiogenic proteins (e.g. Nishimura et al., 1990) , determine the role of speci®c genes with knockout mice (Tobe et al., 1998) , and evaluate the ef®cacy of anti-angiogenic therapies (e.g. Seo et al., 1999) .
The ®rst goal of the current study was to develop an alternative method to measure blood vessel growth in a rat model of experimental CNV. Since high molecular weight FITC-dextran was successfully used for angiography in mouse retinal¯at mounts (D'Amato et al., 1993; Smith et al., 1994) , we employed a similar strategy to label and measure CNV in RPE-choroid-sclera¯at mounts after laser photocoagulation. Combined with H & E and Factor VIII immunostaining is histologic sections, our results clearly establish the temporal and spatial development of functional blood vessels within the lesion after laser photocoagulation. At 3 days after lasering, there is negligible FITC-dextran labeling within lesions, and this parallels the immunohistologic ®nding that Factor-VIII-positive vascular endothelial cells invade the lesion at this time but do not form a functional FIG. 7 . Dose-dependent inhibition of CNV by dexamethasone. Neovascular area was measured by quantitative digital image analysis of FITC-dextran labeled RPE-choroid-sclera¯at mounts. Dexamethasone was suspended in corn oil, and rats were dosed daily by oral gavage. Values are mean + S.D. for three rats per group receiving dexamethasone, and seven rats in the control group. There is a signi®cant difference between neovascularization in the control group and that of all groups treated with dexamethasone (P 5 0 . 05; Bonferroni multiple comparison test). neovascular plexus. By day 6, the incidence and extent of FITC-dextran labeling within lesions signi®-cantly increase, and blood vessels lined with Factor VIII-positive cells are clearly seen in cross section. Results from¯at mounts and cross sections at this time indicate that the neovascular net is derived from deeper choroidal vessels that branch radially in the center of the lesion towards the neural retina, and then laterally and posteriorly towards uninjured choriocapillaris. The radial, anterior growth may be driven by pigment laden cells, presumably macrophages, that are common at this time in the subretinal space in the center of the lesion (Figs 5 and 6 ). By day 10, the neovascular plexus in¯at mounts reaches its maximal size and density, and most lesions contain broad,¯at microvessels that resemble the native choriocapillaris (Dobi et al., 1989) . Similarly, lesion size and blood vessel density in histologic sections are greatest at day 10 and subsequent time points.
The highest growth rate of new choroidal vessels is seen between 3 and 10 days after lasering, and this correlates temporally with increased expression of angiogenic growth factors and their receptors described by previous studies of experimental CNV in rat. For example, bFGF mRNA expression was elevated 3±7 days after lasering, and this endothelial cell mitogen was localized to several cell types within and surrounding the lesion . Similarly, mRNA expression of VEGF and its receptor, VEGFR-2 (¯k-1, KDR), was highest 3±7 days after lasering (Shen et al., 1993; Yi et al., 1997; Wada et al., 1999) . In these studies, bFGF and VEGF/ VEGFR-2 mRNA expression signi®cantly decreased by 2 weeks after lasering. This correlates with our results showing no further increase in the extent of CNV between days 10 and 31 after lasering.
The second goal of this study was to assess the utility of high resolution FITC-dextran angiography to measure drug ef®cacy. The angiostatic corticosteroid dexamethasone was selected because it markedly inhibited corneal (Proia et al., 1993; Edelman, Castro and Wen, 1999) and retinal (Rotschild et al., 1999) neovascularization in rodents, and choroidal neovascularization in primates (Ishibashi et al., 1985) . Our results show that dexamethasone dosedependently inhibited CNV, and its highest dose (500 mg kg À1 day À1 ) nearly completely inhibited blood vessel formation measured by FITC-dextran uorescence in¯at mounts. This ®nding was supported by Factor VIII immunohistochemistry which showed that dexamethasone inhibited the formation of a de®ned cellular lesion and invasion of vascular endothelial cells.
The cellular mechanism(s) by which dexamethasone represses CNV is unclear. One possibility is that dexamethasone indirectly inhibits neovascularization by suppressing the recruitment or altering the function of macrophages or other pro-angiogenic in¯ammatory cells (Anstead, 1998) . Alternatively, dexamethasone may directly affect blood vessel growth as is suggested by its ef®cacy in a model of retinal neovascularization which lacks an obvious in¯ammatory component (Rotschild et al., 1999) . Supporting this, dexamethasone inhibits VEGF production in cultured cells (Nauck et al., 1997) and in vivo (Edelman et al., 1999) , and it reduces capillary-like tube formation and urokinase-type plasminogen activator expression in microvascular endothelial cells (Lansink et al., 1998) . Further studies are required, however, to clarify which of these dexamethasone-sensitive mechanisms underlie the marked inhibition of laser-induced CNV.
Several therapeutic strategies, including a related corticosteroid, triamcinolone, are being tested to treat neovascular ARMD (Challa et al., 1998) . These are anticipated to replace laser photocoagulation of CNV, which is only performed on a limited number of ARMD patients that show a clearly de®ned neovascular lesion (Lee et al., 1998) . For the majority of patients, no accepted treatment for preserving central vision is available. Photodynamic therapy uses targeted laser activation of photosensitive dyes to selectively ablate or close choroidal vessels (SchmidtErfurth et al., 1999) , and this therapy may soon be the standard of care for a limited group of ARMD patients. Small molecule inhibitors of angiogenesis are being developed to treat neovascular ARMD (Ishida et al., 1999; McNatt et al., 1999; Seo et al., 1999) , and these may be useful for treating a larger population of patients in the future. The method of FITC-dextran labeling of CNV described in this study is reproducible and quanti®able, and it may accelerate the discovery of therapeutic interventions to treat choroidal neovascularization.
